MedTrace Logo

Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma

NCT03585673 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-07-17

No results posted yet for this study

Summary

Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed. In this study, The investigators wanted to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly administration chemotherapy for the participants with inoperable or metastatic esophageal squamous cell carcinoma.

Conditions

Interventions

DRUG

Docetaxel-PM

Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression

DRUG

Oxaliplatin

Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression

Sponsors & Collaborators

  • Sung Yong Oh

    lead OTHER

Principal Investigators

  • Sung Yong Oh, MD · Dong-A University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2020-03-30
Completion
2021-03-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03585673 on ClinicalTrials.gov